OBJECTIVE: We asked if patients with metabolic syndrome undergoing total knee replacement (TKR) have an increased risk for symptomatic deep vein thrombosis (DVT) at 3 months followup. METHODS: We reviewed 1460 patients from our joint registry undergoing primary, unilateral TKR between 1998-2006. Demographic variables of age, sex, comorbidity, and education were retrieved. Metabolic syndrome was defined as body mass index above 30 kg/m(2), diabetes, hypertension, and hypercholesterolemia. Logistic regression was used to examine the relationship of metabolic syndrome on the incidence of DVT. RESULTS: The overall incidence of symptomatic DVT was 4.4% (65/1460). Patients with metabolic syndrome had an increased incidence of DVT compared to those without metabolic syndrome (15.5% vs 3.4%). Adjusted analysis showed that the risk of symptomatic DVT in patients with metabolic syndrome was 3.2 times [odds ratio 3.2, 95% CI (1.0,15.4), p = 0.04] the risk in those without metabolic syndrome. CONCLUSION: Hospital protocols developed for prophylactic anticoagulation following TKR should give special consideration to patients with metabolic syndrome.
OBJECTIVE: We asked if patients with metabolic syndrome undergoing total knee replacement (TKR) have an increased risk for symptomatic deep vein thrombosis (DVT) at 3 months followup. METHODS: We reviewed 1460 patients from our joint registry undergoing primary, unilateral TKR between 1998-2006. Demographic variables of age, sex, comorbidity, and education were retrieved. Metabolic syndrome was defined as body mass index above 30 kg/m(2), diabetes, hypertension, and hypercholesterolemia. Logistic regression was used to examine the relationship of metabolic syndrome on the incidence of DVT. RESULTS: The overall incidence of symptomatic DVT was 4.4% (65/1460). Patients with metabolic syndrome had an increased incidence of DVT compared to those without metabolic syndrome (15.5% vs 3.4%). Adjusted analysis showed that the risk of symptomatic DVT in patients with metabolic syndrome was 3.2 times [odds ratio 3.2, 95% CI (1.0,15.4), p = 0.04] the risk in those without metabolic syndrome. CONCLUSION: Hospital protocols developed for prophylactic anticoagulation following TKR should give special consideration to patients with metabolic syndrome.
Authors: Gaia Georgopoulos; Mark S Hotchkiss; Bryan McNair; Georgette Siparsky; Patrick M Carry; Nancy H Miller Journal: J Pediatr Orthop Date: 2016-01 Impact factor: 2.324
Authors: Abd El-Moaty Ali Afifi; Reham Magdy Shaat; OLa M Gharbia; Yosra El Boghdadi; Mervat Mohammad El Eshmawy; Ola Ali El-Emam Journal: Clin Rheumatol Date: 2018-07-23 Impact factor: 2.980